Verastem secures up to $150M from Oberland Capital, repays Oxford loan, NDA accepted with June PDUFA

Verastem, Inc.

Initial $75M notes issued; net proceeds~$32.3M after repaying $42.7M Oxford loan; interest-only 6 years.
Pro forma cash $128.6M including $7.5M equity placement (1.4M shares at $5.2931/share).
FDA accepted NDA for avutometinib+defactinib in KRAS mutant LGSOC; PDUFA June 30, 2025; no AdCom planned.
Revenue participation: Oberland gets 1% of first $100M annual net sales (max 2% if full $150M drawn).
Strategic collaboration with IQVIA to support potential launch mid-2025.

item 1.01 item 1.02 item 2.02 item 2.03 item 3.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.